PCSK9 Inhibitors.

Cell
Authors
Keywords
Abstract

Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular disease.

Year of Publication
2016
Journal
Cell
Volume
165
Issue
5
Pages
1037
Date Published
2016 May 19
ISSN
1097-4172
URL
DOI
10.1016/j.cell.2016.05.016
PubMed ID
27203103
Links